PL354112A1 - Application of anti-ctla-4 antibodies - Google Patents

Application of anti-ctla-4 antibodies

Info

Publication number
PL354112A1
PL354112A1 PL02354112A PL35411202A PL354112A1 PL 354112 A1 PL354112 A1 PL 354112A1 PL 02354112 A PL02354112 A PL 02354112A PL 35411202 A PL35411202 A PL 35411202A PL 354112 A1 PL354112 A1 PL 354112A1
Authority
PL
Poland
Prior art keywords
ctla
antibodies
application
Prior art date
Application number
PL02354112A
Other languages
English (en)
Inventor
Douglas Charles Hanson
Eileen Elliot Mueller
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL354112A1 publication Critical patent/PL354112A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02354112A 2001-05-23 2002-05-23 Application of anti-ctla-4 antibodies PL354112A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
PL354112A1 true PL354112A1 (en) 2002-12-02

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02354112A PL354112A1 (en) 2001-05-23 2002-05-23 Application of anti-ctla-4 antibodies

Country Status (14)

Country Link
US (1) US20030086930A1 (cg-RX-API-DMAC7.html)
EP (1) EP1262193A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002371013A (cg-RX-API-DMAC7.html)
KR (1) KR100531707B1 (cg-RX-API-DMAC7.html)
CN (1) CN1404876A (cg-RX-API-DMAC7.html)
AU (1) AU4242102A (cg-RX-API-DMAC7.html)
CA (1) CA2382443A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20021760A3 (cg-RX-API-DMAC7.html)
HU (1) HUP0201737A2 (cg-RX-API-DMAC7.html)
IL (1) IL149701A0 (cg-RX-API-DMAC7.html)
MY (1) MY136095A (cg-RX-API-DMAC7.html)
PL (1) PL354112A1 (cg-RX-API-DMAC7.html)
SK (1) SK7242002A3 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204020B (cg-RX-API-DMAC7.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2003086459A1 (en) * 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
KR101531400B1 (ko) * 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
GT200400138A (es) 2003-07-22 2005-03-22 Anticuerpos rgi y uso de los mismos.
EP1660537A2 (en) * 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
KR20070067702A (ko) * 2004-11-04 2007-06-28 화이자 프로덕츠 인크. 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
AR053690A1 (es) * 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
AU2006227880A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
EA200800268A1 (ru) * 2005-07-07 2008-06-30 Коли Фармасьютикал Груп, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CA2694034A1 (en) * 2007-07-27 2009-02-05 Pfizer Limited Antibody purification process by precipitation
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
ES2558568T3 (es) * 2008-01-08 2016-02-05 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
DK3446714T3 (da) 2011-06-02 2021-05-10 Univ Louisville Res Found Inc Anti-nucleolinmiddel-konjugerede nanopartikler
JP6563197B2 (ja) 2012-03-13 2019-08-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 卵巣癌の治療のための併用療法
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
KR102274722B1 (ko) * 2012-08-23 2021-07-09 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
MX374291B (es) 2013-08-08 2025-03-06 Cytune Pharma Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
HUE046964T2 (hu) 2013-08-08 2020-04-28 Cytune Pharma Kombinált gyógyászati készítmény
CN105636986B (zh) * 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
US12427173B2 (en) * 2014-03-31 2025-09-30 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
SG11201609032WA (en) * 2014-05-01 2016-12-29 Anaeropharma Science Inc Heterogeneous polypeptide expression cassette
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
RS61470B1 (sr) 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
EP4151231A1 (en) * 2015-02-13 2023-03-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
HRP20201031T1 (hr) * 2015-05-29 2020-10-16 Agenus Inc. Anti-ctla-4 protutijela i postupci njihove upotrebe
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
JP2018523712A (ja) * 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018037595A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
US11013802B2 (en) * 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2019214865B2 (en) * 2018-02-02 2025-04-10 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019179388A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-ctla-4 antibody polypeptide
AU2019251421B2 (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
EP4178571A4 (en) 2020-07-10 2024-07-17 The Regents Of The University Of Michigan GAS41 INHIBITORS AND METHODS OF USE
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Also Published As

Publication number Publication date
CN1404876A (zh) 2003-03-26
US20030086930A1 (en) 2003-05-08
HU0201737D0 (cg-RX-API-DMAC7.html) 2002-07-29
CZ20021760A3 (cs) 2003-05-14
ZA200204020B (en) 2003-11-21
KR100531707B1 (ko) 2005-11-30
JP2002371013A (ja) 2002-12-26
SK7242002A3 (en) 2003-07-01
CA2382443A1 (en) 2002-11-23
EP1262193A1 (en) 2002-12-04
AU4242102A (en) 2002-11-28
IL149701A0 (en) 2002-11-10
HUP0201737A2 (hu) 2003-02-28
KR20020090873A (ko) 2002-12-05
MY136095A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
PL354112A1 (en) Application of anti-ctla-4 antibodies
HUP0402164A3 (en) Polycistronic expression of antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
EP1432444A4 (en) ANTI-BETA ANTIBODIES
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
IL175935A0 (en) Solid forms of anti-egfr antibodies
IL166244A0 (en) Super humanized antibodies
IL160373A0 (en) Antagonistic anti-htnfsf13b human antibodies
EP1441765A4 (en) PROCESS FOR THE PREPARATION OF MONOCATENARY ANTIBODIES
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
EP1455822A4 (en) LYOPHILIZED MONOCLONAL ANTIBODY COMPOSITIONS
AU2002242447A1 (en) Use of polyclonal immunoglobulins
EP1446416A4 (en) TUMOR-SPECIFIC MONOCLONAL ANTIBODIES
ZA200508071B (en) Polycistronic expression of antibodies
GB0121727D0 (en) Monoclonal antibodies
GB0119553D0 (en) Antibodies
GB0118696D0 (en) Novel antibodies
GB0120494D0 (en) Novel antibody
AU2002211364A1 (en) Human anti-cd40 antibodies
GB0119004D0 (en) Antibody

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)